内容紹介
Summary
We conducted a retrospective study to evaluate the efficacy and the problem of the neoadjuvant chemotherapy using DCF for cStage Ⅲ/Ⅳ(squamous cell)esophageal cancer. Eleven patients from January 2017 to December 2018 were enrolled into this study. The median age was 67 years old, male/female ratio was 9 :2, performance status was 0 in all patients, and UICC cStage Ⅲ/Ⅳa was 7 :4. Cycles of chemotherapy was 2 in 1 patients, 3 in 5 patients and additional 2 courses in 1 patient. Four patients switched to FP therapy after a course of DCF. The efficacy of chemotherapy was evaluated by the clinical response rate, average tumor reduction rate, and histological therapeutic effect rate over Grade 2 which was 63.6%, 48.3%, and 40%, respectively. Neutropenia over Grade 3 was observed in all patients and Grade 4 was observed in 6 patients. In conclusion, preoperative chemotherapy with DCF therapy is useful for the treatment of cStage Ⅲ/Ⅳ(squamous cell)esophageal cancer as long as bone marrow suppression is managed.
要旨
cStage Ⅲ,Ⅳ食道癌に対するDCF療法の有用性と問題点を検討した。2017年1月～2018年12月までの当院での11症例を対象とし,腫瘍縮小効果と有害事象について後方視的に検討した。年齢中央値は67歳,男女比は9 :2,PSは全例0であった。化学療法前の病期はcStage Ⅲ 7例,Ⅳa 4例,3コース5例,さらに2コース追加1例,2コースで終了1例,2コース目からFP療法に変更したものが4例であった。化学療法後に手術が可能となったのは5例あった。奏効率63.6%,腫瘍縮小率平均48.3%,組織学的効果はGrade 2以上を2例に認めた。有害事象はGrade 4の好中球減少を全例,Grade 3以上の発熱性好中球減少症を6例に認めた。DCF療法は症例を慎重に選択し,適切な骨髄抑制の対処をすれば有用なNACと考える。
目次
We conducted a retrospective study to evaluate the efficacy and the problem of the neoadjuvant chemotherapy using DCF for cStage Ⅲ/Ⅳ(squamous cell)esophageal cancer. Eleven patients from January 2017 to December 2018 were enrolled into this study. The median age was 67 years old, male/female ratio was 9 :2, performance status was 0 in all patients, and UICC cStage Ⅲ/Ⅳa was 7 :4. Cycles of chemotherapy was 2 in 1 patients, 3 in 5 patients and additional 2 courses in 1 patient. Four patients switched to FP therapy after a course of DCF. The efficacy of chemotherapy was evaluated by the clinical response rate, average tumor reduction rate, and histological therapeutic effect rate over Grade 2 which was 63.6%, 48.3%, and 40%, respectively. Neutropenia over Grade 3 was observed in all patients and Grade 4 was observed in 6 patients. In conclusion, preoperative chemotherapy with DCF therapy is useful for the treatment of cStage Ⅲ/Ⅳ(squamous cell)esophageal cancer as long as bone marrow suppression is managed.
要旨
cStage Ⅲ,Ⅳ食道癌に対するDCF療法の有用性と問題点を検討した。2017年1月～2018年12月までの当院での11症例を対象とし,腫瘍縮小効果と有害事象について後方視的に検討した。年齢中央値は67歳,男女比は9 :2,PSは全例0であった。化学療法前の病期はcStage Ⅲ 7例,Ⅳa 4例,3コース5例,さらに2コース追加1例,2コースで終了1例,2コース目からFP療法に変更したものが4例であった。化学療法後に手術が可能となったのは5例あった。奏効率63.6%,腫瘍縮小率平均48.3%,組織学的効果はGrade 2以上を2例に認めた。有害事象はGrade 4の好中球減少を全例,Grade 3以上の発熱性好中球減少症を6例に認めた。DCF療法は症例を慎重に選択し,適切な骨髄抑制の対処をすれば有用なNACと考える。